FDA Approves Clinical Trial Using Mesenchymal Stem Cells Idiopathic Pulmonary Fibrosis

mesenchymal stem cell

 

 

 

 

 

 

 

 

Researchers at University of Miami Health System receive FDA approval for the first U.S. clinical trial using mesenchymal stem cells to treat idiopathic pulmonary fibrosis. Mesenchymal stem cells are multipotent adult stem cells that can be isolated from bone marrow, teeth, and fat.  Mesenchymal stem cells have demonstrated the ability to differentiate into bone, cartilage, cardiomyocites, muscle, neuronal cells, insulin producing pancreatic beta cells and more.

We believe mesenchymal cells will play an important and expanding role in regenerative medical therapies.  Teeth represent a non-invasive opportunity for individuals to recover and bank their own valuable mesenchymal stem cells as they are collected as an adjunct to routine dental procedures. To learn more about how you can bank your own stem cells to ensure access to future regenerative treatments and therapies, visit www.stemsave.com or call 877-783-6728 (877-StemSave) today.

To view the full article, click here.

The future of Regenerative Medicine is now.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>